跳至主要内容
临床试验/CTRI/2024/07/071178
CTRI/2024/07/071178尚未招募2/3 期

A Clinical study to evaluate the efficacy of Hutabhugadi churna in the management of Pandu roga(Iron deficiency anaemia)

Ch Polika Naga Krishna sai1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年8月20日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
Relief in signs and symptoms and significant improvement of objective parameters

研究概览

简要总结

A clinical trail is done to evaluate the efficacy of the ayurvedic formulation named Hutabhugadi churna in the management of pandu(iron deficiency anaemia) and to validate scientifically the observations that would significantly change the haemoglobin percentage and also relief in signs and symptoms i.e panduta, arohanayasa, agnimandhya, daurbalya, kopana.Hutabhugadi churna is an unique formulation in the management of pandu roga which has its reference from sahasrayogam churna prakarana acts by stimulating jataragni given orally 5gms twice daily with amla uadasvith (sour buttermilk) for 45 days with an assessment for every 15 days for 30 patients of age group between 15-45 years irrespective of gender diagnosed according to subjective and objective parameters and patients suffering from bleeding disorders ,major kidney disease are excluded.The study would be conducted in India aimed to complete in 18 months. Primary outcome measures will be relief in signs and symptoms(subjective parameters) and Secondary outcome will be increase in hemoglobin percentage, changes in peripheral blood smear, mcv, mch. Subjective and objective parameters will be observed before and after the treatment and result assessment is done

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
15.00 Year(s) 至 45.00 Year(s)(—)
性别
All

入选标准

  • Pandu roga diagnosed according to subjective and objective criteria and Mentzer index above 13.

排除标准

  • Anaemia due to internal bleeding, external bleeding, gastric and duodenal ulcer, hemorrhoids, pregnancy induced Anaemia, Leukemia, Major Kidney diseases like ARF, CRF and haemoglobin less than 8gm/dl and above 11gm/dl.

结局指标

主要结局

Relief in signs and symptoms and significant improvement of objective parameters

时间窗: In 45 days period including assessment for every 15 days

次要结局

  • Changes in hemoglobin percentage ,pcv,mcv,mch(Treatment period of 45days)

研究者

发起方
Ch Polika Naga Krishna sai
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Ch Polika Naga Krishna sai

Dr.Achanta lakshmipathi government ayurvedic hospital , vijayawada

研究点 (1)

Loading locations...

相似试验